Marc Fellous

Dr. Fellous joined PMV Pharma in April 2022 as Vice President, Clinical Development and Medical Affairs. Prior to joining PMV Pharma, he was Global Medical Affairs Head on larotrectinib, the first tumor-agnostic drug approved in the U.S. and Europe, and selitrectinib programs at Bayer. He held increasing leadership roles at Bayer and Roche for more than 13 years, contributing to the strategy and launch of multiple successful oncology products. Dr. Fellous completed his doctorate in general medicine at the University Paris V along with a specialized master’s degree in medical management from ESCP-Europe Business School.